Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
Bioxytran (OTCQB: BIXT) commemorates 50 years of mitochondrial research advancement, highlighting the historical significance of fiber optic-based fluorometry in brain mitochondrial research through a landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University.
The company's lead drug candidate BXT-25 is advancing toward Phase 1 trials, targeting conditions requiring oxygen transport carrier capabilities, including:
- Ischemic stroke
- Heart attack
- Pulmonary embolism
- Chronic kidney disease (CKD)
- Long Covid
The research emphasizes real-time mitochondrial monitoring through the MDX Viewer, an FDA-approved device measuring tissue metabolic score. The company is exploring partnerships to integrate next-generation monitoring technologies for patient selection and vital sign measurements.
Bioxytran (OTCQB: BIXT) celebra 50 anni di progressi nella ricerca mitocondriale, evidenziando l'importanza storica della fluorometria basata su fibra ottica nella ricerca mitocondriale cerebrale attraverso un articolo fondamentale del Prof. Avraham Mayevsky dell'Università Bar-Ilan.
Il principale candidato farmaceutico dell'azienda, BXT-25, sta avanzando verso i trial di Fase 1, mirato a condizioni che richiedono capacità di trasporto dell'ossigeno, tra cui:
- Stroke ischemico
- Attacco cardiaco
- Embolia polmonare
- Malattia renale cronica (CKD)
- Long Covid
La ricerca sottolinea il monitoraggio mitocondriale in tempo reale attraverso il MDX Viewer, un dispositivo approvato dalla FDA che misura il punteggio metabolico dei tessuti. L'azienda sta esplorando partnership per integrare tecnologie di monitoraggio di nuova generazione per la selezione dei pazienti e le misurazioni dei segni vitali.
Bioxytran (OTCQB: BIXT) conmemora 50 años de avances en la investigación mitocondrial, destacando la importancia histórica de la fluorometría basada en fibra óptica en la investigación mitocondrial cerebral a través de un artículo fundamental del Prof. Avraham Mayevsky de la Universidad Bar-Ilan.
El principal candidato a fármaco de la empresa, BXT-25, avanza hacia los ensayos de Fase 1, dirigido a condiciones que requieren capacidades de transporte de oxígeno, incluyendo:
- Accidente cerebrovascular isquémico
- Infarto de miocardio
- Embolia pulmonar
- Enfermedad renal crónica (ERC)
- Long Covid
La investigación enfatiza el monitoreo mitocondrial en tiempo real a través del MDX Viewer, un dispositivo aprobado por la FDA que mide el puntaje metabólico del tejido. La empresa está explorando asociaciones para integrar tecnologías de monitoreo de próxima generación para la selección de pacientes y la medición de signos vitales.
Bioxytran (OTCQB: BIXT)는 미토콘드리아 연구의 50년을 기념하며, 바르 일란 대학교의 아브라함 마예프스키 교수의 기념비적인 논문을 통해 뇌 미토콘드리아 연구에서 광섬유 기반 형광 측정의 역사적 중요성을 강조합니다.
회사의 주요 약물 후보인 BXT-25는 산소 운반 능력이 필요한 질환을 대상으로 하여 1상 시험으로 나아가고 있으며, 포함되는 질환은:
- 허혈성 뇌졸중
- 심장마비
- 폐색전증
- 만성 신장 질환 (CKD)
- 롱코비드
이 연구는 조직의 대사 점수를 측정하는 FDA 승인 장치인 MDX Viewer를 통해 실시간 미토콘드리아 모니터링을 강조합니다. 회사는 환자 선택 및 생명 징후 측정을 위한 차세대 모니터링 기술 통합을 위한 파트너십을 탐색하고 있습니다.
Bioxytran (OTCQB: BIXT) commémore 50 ans d'avancées dans la recherche mitochondriale, soulignant l'importance historique de la fluorométrie à base de fibre optique dans la recherche mitochondriale cérébrale à travers un article marquant du Prof. Avraham Mayevsky de l'Université Bar-Ilan.
Le principal candidat médicament de l'entreprise, BXT-25, avance vers des essais de Phase 1, ciblant des conditions nécessitant des capacités de transport d'oxygène, notamment :
- Accident vasculaire cérébral ischémique
- Crise cardiaque
- Embolie pulmonaire
- Maladie rénale chronique (MRC)
- Long Covid
La recherche met l'accent sur la surveillance mitochondriale en temps réel grâce au MDX Viewer, un dispositif approuvé par la FDA mesurant le score métabolique des tissus. L'entreprise explore des partenariats pour intégrer des technologies de surveillance de nouvelle génération pour la sélection des patients et les mesures des signes vitaux.
Bioxytran (OTCQB: BIXT) feiert 50 Jahre Fortschritte in der mitochondrialen Forschung und hebt die historische Bedeutung der faseroptischen Fluorometrie in der Gehirnmitochondrienforschung durch eine wegweisende Arbeit von Prof. Avraham Mayevsky von der Bar-Ilan-Universität hervor.
Der Hauptkandidaten des Unternehmens, BXT-25, schreitet in Richtung Phase-1-Studien voran, mit dem Ziel von Erkrankungen, die Fähigkeiten zum Transport von Sauerstoff benötigen, einschließlich:
- Ischämischer Schlaganfall
- Herzinfarkt
- Lungenembolie
- Chronische Nierenerkrankung (CKD)
- Long Covid
Die Forschung betont die Echtzeit-Monitoring von Mitochondrien durch den MDX Viewer, ein von der FDA zugelassenes Gerät zur Messung des Gewebe-Metabolismuscores. Das Unternehmen erkundet Partnerschaften zur Integration von Technologien der nächsten Generation für die Patientenauswahl und Vitalzeichenmessungen.
- BXT-25 advancing to Phase 1 trials for multiple major medical conditions
- Integration with FDA-approved MDX Viewer device for real-time monitoring
- Potential partnerships for next-generation monitoring technologies
- Still in pre-clinical phase with no human trial data yet
- Multiple competing indications may complicate development pathway
- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases
- Leading drug candidate ProLectin-M targets galectins in viral infections including bird flu like viruses
BOSTON, MASSACHUSETTS, April 11, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel therapies targeting hypoxia and mitochondrial dysfunction, today highlighted the historical and scientific significance of fiber optic–based fluorometry in brain mitochondrial research. A landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University was published in a book compiled by editor George Laliotis which covered key areas of biological science. Bioxytran believes this is a milestone achievement because the study, commemorates 50 years of in vivo NADH redox state monitoring, highlighting the pivotal role of mitochondrial function in cellular health. This is a cornerstone of Bioxytran’s BXT-25 drug development program.
https://doi.org/10.1117/1.JBO.30.S2.S23902
The recent paper emphasizes the significance of real-time mitochondrial monitoring, particularly in addressing mitochondrial dysfunction and hypoxia—key contributors to diseases like stroke.
The groundbreaking work of Prof. Mayevsky, which introduced UV-transmitting optical fibers for tracking NADH fluorescence in vivo, paved the way for development of the MDX Viewer with is an FDA approved device that measures tissue metabolic score in real time.
Bioxytran is advancing BXT-25 toward Phase 1 trials for conditions where an oxygen transport carrier is needed to burrow through blood clots including ischemic stroke, heart attack, pulmonary embolism, chronic kidney disease (CKD), and Long Covid. The company is also exploring partnerships to integrate next-generation monitoring technologies for patient selection and use as a new vital sign.
“This anniversary paper mirrors our mission at Bioxytran —to translate decades of foundational science into life-saving therapies,” stated David Platt, CEO of Bioxytran Inc. “BXT-25 builds on these principles by directly addressing the mitochondrial dysfunction observed in hypoxia-related diseases. Prof. Mayevsky’s work validates the urgency of our clinical efforts."
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. For more information, visit www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What medical conditions is Bioxytran's BXT-25 targeting in Phase 1 trials?
How does BIXT's BXT-25 technology relate to mitochondrial research?
What monitoring technology is being used with BIXT's BXT-25 development?
What is the significance of Prof. Mayevsky's research for BIXT's drug development?
